These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38218655)

  • 1. Immunotherapy in multiple myeloma.
    Asensi Cantó P; Arnao Herraiz M; de la Rubia Comos J
    Med Clin (Barc); 2024 May; 162(10):485-493. PubMed ID: 38218655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
    Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
    Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E
    Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
    Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; Ye JC; Sidhana S; Merlini G; Martin T; Lin Y; Chari A; Popat R; Kaufman JL;
    Lancet Oncol; 2024 May; 25(5):e205-e216. PubMed ID: 38697166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-based therapies in the management of multiple myeloma.
    Zanwar S; Nandakumar B; Kumar S
    Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
    Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies for multiple myeloma: past, present and future.
    Ochi T; Konishi T; Takenaka K
    Int J Hematol; 2024 Jul; 120(1):23-33. PubMed ID: 38613724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.